03.08.2010 • NewsChemturabankruptcyGoldman Sachs

Bankrupt Chemtura Seeks $1.025 Billion Exit Financing

Bankrupt U.S. chemicals company Chemtura Corp has asked a judge to approve $1.025 billion in bankruptcy exit financing to help the company fund operations after it emerges from Chapter 11 protection, according to court documents.

The specialty chemicals maker is urging speed, saying it wants to lock in the agreements now to take advantage of favorable high-yield debt markets and move ahead of the September Labor Day holiday, when financial markets are closed.

"Even a short delay in the pricing and funding of the notes and term loan could result in long-term financing costs to the reorganized debtors," said Chemtura in court documents filed late on Friday.

Chemtura, which makes chemicals for crop protection and spa care, said the agreements include a $275 million asset-based revolving credit facility and $750 million of senior notes or term loan, or some combination of the two.

Banc of America Securities and Wells Fargo Finance are named as the joint lead arrangers for the revolving credit facility. Term loan joint lead arrangers are Banc of America, Wells Fargo and Citigroup Global Markets.

Chemtura has agreed to sell the senior notes to a group of initial purchasers which include Citigroup, Banc of America Barclays Capital and Goldman Sachs.

The company filed for bankruptcy last year after a global decline in demand for chemicals.

The company has proposed a hearing to confirm its plan of reorganization on Sept. 16 and expects the plan to be effective before Sept. 30.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

most read

Photo
21.03.2025 • News

What’s Next for Pharma Supply Chains?

Sudden shifts in demand, supply shortages and global collapse have put immense pressure on pharmaceutical logistics. To address these challenges, PHARMAP 2025 brings together industry experts to discover AI-driven supply chain optimisation, strategic logistics partnerships and digital solutions that enhance efficiency and resilience in the pharmaceutical supply chain.